Semax: The Russian Nootropic Peptide
Semax Nootropic Research
1.4x BDNF increase
A single intranasal dose of Semax produced a 1.4-fold increase in BDNF protein levels and a 3-fold increase in BDNF mRNA in the rat hippocampus.
Dolotov et al., Brain Research, 2006
Dolotov et al., Brain Research, 2006
View as imageSemax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4-10) fragment of adrenocorticotropic hormone. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences by researchers under the guidance of I.P. Ashmarin and N.F. Myasoedov, it has been on Russia's List of Vital and Essential Drugs since 2011. A single intranasal dose in rats produces a 1.4-fold increase in BDNF protein and a 3-fold increase in BDNF mRNA in the hippocampus.[1] Outside Russia, Semax has no regulatory approval, no Phase III trials in Western regulatory systems, and limited clinical data by Western evidence standards. This article examines what the preclinical and clinical research actually demonstrates. For how Semax fits into the broader landscape of cognitive-enhancing peptides, see Nootropic Peptides: A Scientific Overview of Cognitive Enhancers.
Key Takeaways
- Semax (ACTH 4-10 analog) upregulates BDNF protein 1.4-fold and BDNF mRNA 3-fold in the rat hippocampus after a single intranasal dose of 50 mcg/kg, with concurrent 1.6-fold increase in TrkB receptor phosphorylation
- Romanova et al. (2006) showed Semax decreased ischemic infarct volume in rats when administered intranasally for 6 days after photoinduced prefrontal cortex ischemia
- Eremin et al. (2005) demonstrated Semax activates both dopaminergic and serotonergic brain systems within 30 minutes of intranasal administration in rats
- Inozemtseva et al. (2024) found Semax produced antidepressant-like effects in multiple rodent stress models, with efficacy comparable to the PGP tripeptide fragment
- A 2025 study by Liu et al. identified a novel mechanism: Semax promotes deubiquitination of mu opioid receptors, stabilizing lysosomal membranes after spinal cord injury
- Semax is approved in Russia for ischemic stroke and cognitive disorders but has no FDA or EMA approval, and most clinical data comes from Russian-language publications
What Semax is and how it was designed
Semax consists of the ACTH(4-10) sequence (Met-Glu-His-Phe-Pro-Gly-Pro) with the C-terminal tripeptide Pro-Gly-Pro (PGP) added to extend its biological half-life. The ACTH(4-10) fragment retains the melanocortin receptor activity that influences attention, learning, and memory without the adrenal steroidogenic effects of full-length ACTH. Full-length ACTH stimulates cortisol production; ACTH(4-10) does not. This decoupling of cognitive effects from hormonal effects was the rationale for developing Semax as a nootropic.
The PGP extension is not pharmacologically inert. PGP itself has immunomodulatory and anti-inflammatory properties, and Inozemtseva et al. (2024) showed that both Semax and PGP independently produce antidepressant-like and antistress effects in rodent models.[2] The combination may produce effects that neither fragment achieves alone.
Semax is administered intranasally, typically as a 0.1% or 1% nasal spray solution. The intranasal route allows partial bypassing of the blood-brain barrier through direct nose-to-brain transport via the olfactory and trigeminal nerve pathways. This is the same delivery principle used for other neuropeptide therapeutics. For more on this mechanism, see Semax Nasal Delivery: How It Reaches the Brain.
BDNF upregulation: the central mechanism
The most consistently replicated finding in Semax research is its effect on brain-derived neurotrophic factor (BDNF). BDNF is a protein critical for neuronal survival, synaptic plasticity, and memory formation. Low BDNF levels are associated with depression, cognitive decline, and neurodegeneration.
Dolotov et al. (2006) provided the detailed mechanistic picture. A single intranasal application of Semax at 50 mcg/kg body weight in rats produced:[1]
- 1.4-fold increase in BDNF protein levels in the hippocampus
- 3-fold increase in exon III BDNF mRNA
- 2-fold increase in TrkB receptor mRNA
- 1.6-fold increase in TrkB tyrosine phosphorylation (receptor activation)
The earlier Dolotov et al. (2003) study had already demonstrated that Semax stimulates BDNF expression across multiple brain regions, not just the hippocampus.[3] The 2006 study added the critical finding that Semax also upregulates and activates TrkB, the receptor through which BDNF signals. Increasing BDNF without increasing its receptor would have limited functional impact; Semax appears to enhance both sides of the signaling pathway.
This BDNF mechanism is detailed further in How Semax Upregulates BDNF: The Neuroplasticity Mechanism. For broader context on how peptides influence brain plasticity, see How Peptides Can Modulate Neuroplasticity: Mechanisms and Evidence.
Neurotransmitter effects
Semax does not act exclusively through BDNF. Eremin et al. (2005) demonstrated that Semax activates both dopaminergic and serotonergic brain systems.[4] Within 30 minutes of intranasal administration in rats, Semax increased the turnover of dopamine and serotonin in brain regions associated with motivation, attention, and mood regulation. This rapid timescale suggests a direct receptor-mediated effect rather than a secondary consequence of BDNF upregulation, which takes hours.
The dual neurotransmitter activation has implications for understanding Semax's reported cognitive effects. Dopamine is central to attention, working memory, and reward processing. Serotonin modulates mood, anxiety, and impulse control. A compound that simultaneously enhances both systems could theoretically improve cognitive performance through multiple converging pathways.
Tsai (2007) proposed Semax as a potential agent for attention-deficit hyperactivity disorder (ADHD) based on its dopaminergic activation profile and melanocortin receptor activity.[5] This remains a hypothesis. No clinical trials of Semax for ADHD have been conducted.
Neuroprotection in stroke models
The largest body of Semax clinical research centers on ischemic stroke. In Russia, Semax is approved for use in the acute period of hemispheric ischemic stroke, where it is administered as a 1% nasal spray.
Preclinical evidence
Romanova et al. (2006) demonstrated pronounced neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction in rats.[6] Intranasal administration for 6 days after photoinduced ischemia of the prefrontal cortex decreased the volume of cortical infarction. The effect was dose-dependent and accompanied by preservation of memory function that was lost in untreated ischemic animals.
Sudarkina et al. (2021) used proteomics to map the brain protein expression changes caused by Semax treatment after ischemia-reperfusion injury in rats.[7] The analysis confirmed that Semax's protective effect involves multiple protein pathways, including anti-apoptotic signaling, anti-inflammatory cascades, and neurotrophic factor production. This is consistent with the multi-mechanism profile seen across other Semax studies.
Medvedeva et al. (2017) found that Semax regulates expression of immune response genes during ischemia in the rat brain, suggesting that its neuroprotective effects are partially mediated through modulation of the inflammatory response that follows stroke.[8] The immunomodulatory and vascular effects of Semax during ischemia may be as important as its neurotrophic activity for stroke outcomes.
Clinical evidence
Russian clinical studies have evaluated Semax in stroke patients, though most of this literature is published in Russian-language journals with limited availability of raw data. A study of 30 patients in the acute period of hemispheric ischemic stroke found that adding Semax to standard intensive therapy increased the rate of neurological recovery, particularly for motor function. A separate study evaluated efficacy across different stages of ischemic stroke.
The evidence quality is difficult to assess by Western standards. Sample sizes have been small, many studies lack placebo controls or blinding, and the full trial protocols are not always available in English. Semax's Russian regulatory approval is based on this clinical evidence, but the compound has not undergone the Phase III trials that the FDA or EMA would require for approval. For the specific stroke recovery evidence, see Semax for Stroke Recovery: Neuroprotection Evidence.
Antidepressant and antistress effects
Inozemtseva et al. (2024) evaluated Semax and its PGP fragment for antidepressant-like and antistress effects using multiple validated rodent models of depression and anxiety.[2] Both Semax and PGP reduced immobility in the forced swim test and tail suspension test (standard measures of antidepressant-like activity in rodents). Both also attenuated stress-induced behavioral changes.
The finding that PGP alone produces antidepressant effects is mechanistically interesting because it suggests the C-terminal extension added to ACTH(4-10) to create Semax is not merely a half-life extender but contributes its own pharmacological activity. The authors proposed that the antidepressant effects operate through multiple pathways, including melanocortin receptor activation (from the ACTH fragment) and immunomodulation (from the PGP fragment).
Glazova et al. (2021) showed that Semax attenuates behavioral and neurochemical alterations caused by prenatal SSRI exposure in rats.[9] Rats exposed to fluoxetine during fetal development showed altered serotonin metabolism and anxiety-like behavior as adults; Semax administration normalized both. This suggests potential applications in neurodevelopmental disorders, though the distance from rat model to human therapy is substantial.
Newer discoveries: opioid receptors and spinal cord injury
The most recent expansion of Semax research moves beyond its established BDNF and stroke applications. Liu et al. (2025) identified a previously unknown mechanism: Semax targets the mu opioid receptor gene Oprm1, promoting deubiquitination and stabilizing lysosomal membranes after spinal cord injury (SCI).[10]
Lysosomal membrane permeabilization (LMP) worsens cell death after SCI. Liu et al. showed that Semax stabilizes lysosomal membranes by modulating ubiquitination of the mu opioid receptor, reducing neuronal cell death in SCI models. This mechanism is entirely separate from BDNF upregulation or neurotransmitter modulation, suggesting Semax has pharmacological effects beyond what its melanocortin receptor activity would predict.
Radchenko et al. (2025) explored Semax's potential for correcting pathological processes in Alzheimer's disease models, finding effects on amyloid aggregation and neuroinflammation pathways.[11] Tabbi et al. (2015) had earlier shown that Semax has high affinity for copper(II) ions and can modulate copper-induced amyloid-beta aggregation in membrane models, offering a biophysical explanation for potential anti-Alzheimer effects.[12]
Comparison with other nootropic peptides
Semax belongs to a class of synthetic neuropeptide analogs developed primarily in Russia and the former Soviet Union. Its closest relative is Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro), derived from the endogenous immunomodulatory peptide tuftsin rather than ACTH. While Semax primarily targets BDNF and dopaminergic pathways, Selank acts primarily through serotonergic and GABAergic systems. A detailed comparison is available in Selank vs Semax: How Two Russian Neuropeptides Compare.
Noopept (GVS-111) is often grouped with Semax but is not technically a peptide; it is a dipeptide-derived small molecule that acts through different mechanisms. See Noopept: The Peptide-Derived Nootropic (And Why It's Not Technically a Peptide) for the distinction.
Other neuroprotective peptides that have reached more advanced clinical development in Western regulatory systems include davunetide (NAP), covered in NAP Peptide (Davunetide): A Neuroprotective Peptide That Reached Clinical Trials.
What remains uncertain
Semax has a substantial research base, but several gaps limit confidence in its clinical utility:
Limited Western clinical data. The majority of clinical evidence comes from Russian studies with small sample sizes, limited blinding, and publication in Russian-language journals. No multicenter randomized controlled trials meeting FDA or EMA standards have been completed.
Mechanism complexity. Semax affects BDNF, dopamine, serotonin, immune response genes, opioid receptors, and copper metabolism. This breadth could indicate a genuinely multi-target drug, or it could indicate that researchers have been measuring many endpoints without establishing which are causal and which are downstream correlates. The relative contribution of each mechanism to cognitive or neuroprotective effects in humans is unknown.
Dose-response in humans. While animal studies use standardized dosing (typically 50-600 mcg/kg intranasally), human dosing protocols vary across Russian clinical reports, and systematic dose-finding studies with modern pharmacokinetic methods are lacking.
Long-term safety. Despite decades of use in Russia, long-term safety data from controlled studies is sparse. BDNF upregulation, while generally considered beneficial, could theoretically promote unwanted neural growth in susceptible individuals.
Regulatory translation. Semax's Russian approval does not easily translate to other markets. The clinical evidence package that satisfied Russian regulators would likely not meet the requirements of the FDA, EMA, or other major regulatory bodies without additional trials.
The Bottom Line
Semax is a well-studied synthetic peptide with consistent preclinical evidence for BDNF upregulation, dopaminergic and serotonergic activation, and neuroprotection in stroke models. It is approved in Russia for ischemic stroke and cognitive disorders. Recent research has expanded its known mechanisms to include opioid receptor modulation and anti-amyloid effects. The primary limitation is the absence of large-scale, Western-standard clinical trials, which means the translation from strong animal data and limited Russian clinical reports to established therapeutic use outside Russia remains incomplete.